Phase II trial of irinotecan plus celeco
โ
David A. Reardon; Jennifer A. Quinn; James Vredenburgh; Jeremy N. Rich; Sridhara
๐
Article
๐
2005
๐
John Wiley and Sons
๐
English
โ 219 KB
## Abstract ## BACKGROUND In the current study, the authors report a Phase II trial of irinotecan (CPTโ11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COXโ2 inhibitor, among MG patients with recurrent disease. ## METHODS Patients with MG at any